Catalent Signs Commercial Manufacturing Agreement With US WorldMeds For Lofexidine




SOMERSET, N.J. – September 5, 2017 — Catalent Pharma Solutions, the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced it has entered into an exclusive agreement with US WorldMeds, LLC for the commercial manufacture of lofexidine, an investigational drug under development to mitigate symptoms associated with opioid withdrawal and facilitate completion of opioid discontinuation treatment.

US WorldMeds has the rights to commercialize lofexidine in the U.S., which is currently approved as Britlofex™ in the United Kingdom. Catalent and US WorldMeds have worked together to successfully tech transfer the manufacturing from a facility overseas to Catalent’s Winchester, Kentucky, facility, where they have produced registration batches to support US WorldMeds’ New Drug Application to the Food and Drug Administration (FDA) and the anticipated commercial launch.

Lofexidine received Fast Track designation by the FDA, a process designed to expedite the review of drugs that treat serious conditions and address an unmet medical need. If approved, lofexidine would be the first non-narcotic and non-addictive medication in the United States for treatment of symptoms associated with opioid withdrawal.

“Symptoms of opioid withdrawal can be a significant barrier in seeking help and breaking the cycle of dependence and addiction,” said Jonathan Arnold, Catalent's ‎vice president and general manager, Drug Delivery Solutions. “We are excited to join forces with US WorldMeds to bring a potential new treatment option to a major health issue spanning the nation.” 

Catalent’s Winchester, facility has more than 20 years’ experience in product development, technology transfer and commercial manufacturing. The site has produced over three billion tablets and capsules annually and launched more than 100 new products into the market since its inception.

Media Contacts:

Chris Halling
+44 (0)7580 041073
chris.halling@catalent.com

Richard Kerns
+44 (0) 161 728 5880
richard@nepr.eu

About Catalent

Catalent is the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products. With over 80 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable clinical and commercial product supply. Catalent employs approximately 10,000 people, including over 1,400 scientists, at more than 30 facilities across five continents, and in fiscal 2017 generated more than $2 billion in annual revenue. Catalent is headquartered in Somerset, New Jersey. For more information, visit www.catalent.com

More products. Better treatments. Reliably supplied.™